Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer. PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system. Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology. The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors. ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others. To read the Full Publication, visit https://ibn.fm/Lhc3W For further information about Onco-Innovations, visit the Onco-Innovations profile.   To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com